Denmark’s neuroscience-focused pharma firm Lundbeck has agreed to pay $1.95 billion to acquire Seattle-based Alder BioPharmaceuticals to boost its late-stage pipeline and biologics capabilities.
Barely a year at the helm, Lundbeck CEO Deborah Dunsire (pictured) is making her second major acquisition as she continues to look for new growth drivers to offset generics erosion of the firm’s top-selling epilepsy treatment clobazam (Onfi), which lost US patent exclusivity in October 2018. The acquisition of Alder (NASDAQ: ALDR) will include eptinezumab, a migraine drug that is under marketing review at the FDA, which will make an approval decision by next February 21…. Read more »
UNDERWRITERS AND PARTNERS
